Categories: Endocrine diseases

Aliases & Classifications for Hyperpituitarism

MalaCards integrated aliases for Hyperpituitarism:

Name: Hyperpituitarism 12 41 14 69


External Ids:

Disease Ontology 12 DOID:2444
MeSH 41 D006964
UMLS 69 C0020506

Summaries for Hyperpituitarism

MalaCards based summary : Hyperpituitarism is related to hyperthyroidism and hypopituitarism. An important gene associated with Hyperpituitarism is IGF1 (Insulin Like Growth Factor 1), and among its related pathways/superpathways are TGF-Beta Pathway and Peptide ligand-binding receptors. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and brain, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Wikipedia : 72 Hyperpituitarism is a condition due to the primary hypersecretion of pituitary hormones, it typically... more...

Related Diseases for Hyperpituitarism

Diseases related to Hyperpituitarism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 130)
# Related Disease Score Top Affiliating Genes
1 hyperthyroidism 28.8 GH1 INS PRL SST TRH
2 hypopituitarism 27.6 GH1 GHRH IGF1 IGFBP3 INS POMC
3 galactorrhea 10.4 IGF1 PRL
4 bronchus adenoma 10.4 POMC SST
5 glucagonoma 10.4 GHRH SST
6 bronchial adenomas/carcinoids childhood 10.4 POMC SST
7 prolactin producing pituitary tumor 10.4 PRL SST
8 generalized resistance to thyroid hormone 10.4 PRL TRH
9 pancreatic cholera 10.4 GHRH SST
10 pituitary carcinoma 10.3 POMC SST
11 slipped capital femoral epiphysis 10.3 IGF1 IGFBP3
12 fasting hypoglycemia 10.3 IGF1 POMC
13 suprasellar meningioma 10.3 POMC TRH
14 fibrous dysplasia/mccune-albright syndrome 10.3 GH1 PRL
15 acth-secreting pituitary adenoma 10.3 POMC PRL
16 diffuse idiopathic skeletal hyperostosis 10.3 IGF1 IGFBP3
17 carcinoid syndrome 10.3 GHRH IGF1 SST
18 multiple endocrine neoplasia, type iv 10.3 AIP PRL
19 osteoporosis, juvenile 10.2 IGF1 IGFBP3
20 acidophil adenoma 10.2 IGF1 POMC SST
21 acid-labile subunit deficiency 10.2 IGF1 IGFBP3
22 lymphocytic hypophysitis 10.2 GH1 POMC
23 persistent fetal circulation syndrome 10.2 IGF1 POMC
24 hormone producing pituitary cancer 10.2 AIP IGF1 SST
25 diabetes insipidus, neurohypophyseal 10.2 POMC PRL
26 central nervous system organ benign neoplasm 10.2 IGF1 POMC PRL
27 chiasmal syndrome 10.2 POMC PRL SST
28 nelson syndrome 10.2 POMC PRL SST
29 hypoadrenalism 10.2 GH1 POMC
30 adrenal cortex disease 10.2 POMC PRL SST
31 adrenal gland disease 10.2 POMC PRL SST
32 sella turcica neoplasm 10.1 GHRH POMC PRL
33 tuberculum sellae meningioma 10.1 GHRH POMC PRL
34 ectopic cushing syndrome 10.1 POMC SST
35 growth hormone secreting pituitary adenoma 10.1 AIP PRL SST
36 tetrahydrobiopterin deficiency 10.1 GH1 PRL
37 acromesomelic dysplasia, maroteaux type 10.1 GHR IGF1
38 marasmus 10.1 GH1 IGFBP3
39 tsh producing pituitary tumor 10.1 GH1 PRL SST
40 mammographic density 10.1 IGF1 IGFBP3 PRL
41 amenorrhea 10.1 POMC PRL TRH
42 premenstrual tension 10.1 POMC PRL
43 pancreatic islet cell tumors 10.1 INS SST
44 breast disease 10.1 IGF1 IGFBP3 PRL
45 duodenal somatostatinoma 10.1 INS SST
46 postgastrectomy syndrome 10.1 INS SST
47 postural hypotension 10.1 INS SST
48 hyperinsulinemic hypoglycemia, familial, 2 10.0 INS SST
49 donohue syndrome 10.0 IGF1 INS
50 graves' disease 10.0

Graphical network of the top 20 diseases related to Hyperpituitarism:

Diseases related to Hyperpituitarism

Symptoms & Phenotypes for Hyperpituitarism

MGI Mouse Phenotypes related to Hyperpituitarism:

# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.02 GHR POMC GHRH PRL IGF1 TRH
2 growth/size/body region MP:0005378 9.97 AIP INS GHR POMC GHRH IGF1
3 homeostasis/metabolism MP:0005376 9.96 GHR POMC GHRH PRL IGF1 SST
4 adipose tissue MP:0005375 9.8 INS GHR POMC IGF1 IGFBP3
5 integument MP:0010771 9.7 GHR POMC PRL IGF1 IGFBP3 AIP
6 liver/biliary system MP:0005370 9.5 GHR POMC GHRH PRL IGFBP3 AIP
7 nervous system MP:0003631 9.23 INS GHR POMC GHRH PRL IGF1

Drugs & Therapeutics for Hyperpituitarism

Drugs for Hyperpituitarism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
Dopamine Approved Phase 4,Phase 3,Phase 1,Phase 2 51-61-6, 62-31-7 681
Risperidone Approved, Investigational Phase 4,Phase 3 106266-06-2 5073
Octreotide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 83150-76-9 6400441 383414
Somatostatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 38916-34-6, 51110-01-1 53481605
6 lanreotide Approved Phase 4,Phase 3,Phase 2,Phase 1 108736-35-2
Quinagolide Approved, Investigational Phase 4 87056-78-8, 97805-50-0 105105
Cabergoline Approved Phase 4,Phase 3,Phase 2 81409-90-7 54746
Liraglutide Approved Phase 4 204656-20-2 44147092
Metformin Approved Phase 4 657-24-9 4091 14219
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
Lactitol Investigational Phase 4,Phase 3,Phase 1 585-86-4 3871
14 Antipsychotic Agents Phase 4,Phase 3,Phase 2
15 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
16 Dopamine Agents Phase 4,Phase 3,Phase 1,Phase 2
17 Dopamine Antagonists Phase 4,Phase 3
18 Dopamine D2 Receptor Antagonists Phase 4
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
20 Paliperidone Palmitate Phase 4
21 Psychotropic Drugs Phase 4,Phase 3,Phase 2
Serotonin Phase 4,Phase 3 50-67-9 5202
23 Serotonin 5-HT2 Receptor Antagonists Phase 4
24 Serotonin Agents Phase 4,Phase 3
25 Serotonin Antagonists Phase 4,Phase 3
26 Tranquilizing Agents Phase 4,Phase 3,Phase 2
27 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
28 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
29 insulin Phase 4,Phase 3,Phase 2
30 Insulin, Globin Zinc Phase 4,Phase 3,Phase 2
31 Mitogens Phase 4,Phase 3,Phase 2
32 Complement Factor I Phase 4,Phase 3
33 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
34 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
35 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
36 Dopamine agonists Phase 4,Phase 3,Phase 1,Phase 2
37 Antiparkinson Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Protective Agents Phase 4,Phase 1,Phase 2
39 Angiopeptin Phase 4,Phase 3,Phase 2,Phase 1
40 Autonomic Agents Phase 4,Phase 2,Phase 1
41 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 1
42 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
43 Hypoglycemic Agents Phase 4,Phase 2
44 Liver Extracts Phase 4
45 Dipeptidyl-Peptidase IV Inhibitors Phase 4
46 HIV Protease Inhibitors Phase 4
47 Incretins Phase 4
protease inhibitors Phase 4
49 Sitagliptin Phosphate Phase 4
50 Estradiol 17 beta-cypionate Phase 4

Interventional clinical trials:

(show top 50) (show all 194)

# Name Status NCT ID Phase Drugs
1 A Multicenter Study to Evaluate the Effects of Switching to Aripiprazole 12 Weeks on the Sexual Dysfunction From Risperidone or Paliperidone in Patients With Schizophrenia Spectrum Disorders or Bipolar Spectrum Disorders Unknown status NCT01742390 Phase 4 Aripiprazole;risperidone or paliperidone
2 Effects of Sandostatin LAR® in Acromegaly Unknown status NCT01424241 Phase 4 Sandostatin LAR
3 Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) Unknown status NCT00915954 Phase 4
4 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
5 Changes of Left Ventricular Mass and Cardiac Function in Patients With Active Acromegaly During Treatment With the Growth Hormone Receptor Antagonist Pegvisomant Unknown status NCT00552851 Phase 4 pegvisomant
6 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
7 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
8 Endometriosis Patients Undergoing Quinagolide Treatment Completed NCT00625950 Phase 4
9 Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target Completed NCT01618513 Phase 4 Sandostatin® LAR
10 Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Completed NCT01278342 Phase 4 Sandostatin LAR;pegvisomant;cabergoline
11 Short and Long Term Efficacy of Combined Cabergoline and Octreotide Treatment in Acromegalic Patients Completed NCT01014793 Phase 4 cabergoline
12 Non Interventional Study For Patients Treated With Somavert® Completed NCT00858143 Phase 4
13 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects Completed NCT00701363 Phase 4 Lanreotide Autogel 120 mg
14 Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients Completed NCT00642720 Phase 4 Pegvisomant
15 Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly Completed NCT00627796 Phase 4 Lanreotide-Autogel 120 mg
16 Acute Application of Pegvisomant and Octreotide in Acromegaly Completed NCT00595140 Phase 4 pegvisomant;combination with somatostatin analogue octreotide;combination with dopamine agonist cabergoline
17 Preoperative Octreotide Treatment of Acromegaly Completed NCT00521300 Phase 4 Octreotide
18 Predictive Factors of Response to Somatostatin Analogues in Acromegalic Patients With Persistent Disease Following Surgery Completed NCT00500227 Phase 4
19 Dose Escalation of Octreotide-LAR as First-Line Therapy in Resistant Acromegaly Completed NCT00461149 Phase 4 Octreotide-LAR
20 Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly Completed NCT00376064 Phase 4 Octreotide acetate and cabergoline/Octrotide and Somavert
21 A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide Completed NCT00234520 Phase 4
22 Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR Completed NCT00216398 Phase 4 Lanreotide (Autogel formulation)
23 Octreotide Efficacy and Safety in First-line Acromegalic Patients Completed NCT00171886 Phase 4 Octreotide
24 Canadian Pegvisomant Compassionate Study In Acromegalic Patients Completed NCT00151437 Phase 4 Pegvisomant treatment
25 Somatuline Autogel: Acromegaly Self/Partner Injection Study Completed NCT00149188 Phase 4 Lanreotide (Autogel formulation)
26 Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction Completed NCT00145405 Phase 4 Lanreotide Autogel and Octreotide LAR
27 A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly Completed NCT00068042 Phase 4 Pegvisomant;Sandostatin LAR
28 Pegvisomant And Sandostatin LAR Combination Study Completed NCT00068029 Phase 4 Pegvisomant/ Sandostatin LAR;Sandostatin LAR;Pegvisomant
29 Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues Recruiting NCT02427295 Phase 4 Sandostatin (Octreotide Acetate)
30 Assessment of Changes in Metabolic Activity in Liver & Skeletal Muscle in Patients Suffering From Acromegaly Recruiting NCT02115906 Phase 4
31 Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly Recruiting NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
32 Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Recruiting NCT01794793 Phase 4 Pasireotide
33 Pasireotide LAR and Pegvisomant Study in Acromegaly Active, not recruiting NCT02668172 Phase 4 Pasireotide LAR 60 mg;Pegvisomant
34 A Pilot Study of Pre- and Post-operative Use of Somatuline Depot. Terminated NCT01861717 Phase 4 lanreotide
35 The Luveris In Vitro Fertilization Trial Terminated NCT00889512 Phase 4 Luveris fixed dose;Luveris increasing dose
36 Study Assessing the Efficacy and Safety of Octreotide Acetate in Patients With Acromegaly, With Micro or Macroadenomas Terminated NCT00242541 Phase 4 Octreotide acetate
37 Risperidone-Induced Hyperprolactinemia Treated With Bromocriptine Unknown status NCT00315081 Phase 3 Bromocriptin
38 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease. Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
39 Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease Completed NCT01374906 Phase 3 SOM230 LAR 30 mg;SOM230 LAR 10 mg
40 Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia Completed NCT00799383 Phase 3 Calcium and Vitamin D
41 Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
42 Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly Completed NCT02493517 Phase 3 Lanreotide Autogel®;Lanreotide Acetate
43 Efficacy and Safety of Octreotide (MYCAPSSA™ [Formerly Octreolin™]) for Acromegaly Completed NCT01412424 Phase 3 Octreotide capsules
44 Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly Completed NCT01137682 Phase 3 Pasireotide (SOM230);octreotide LAR 30mg;lanreotide ATG 120mg
45 Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma Completed NCT00690898 Phase 3 Lanreotide autogel 120 mg
46 Open Label Extension Study Evaluating Safety and Biological Activity of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00635765 Phase 3 C2L-OCT-01 PR 30 mg
47 Efficacy and Safety of C2L-OCT-01 PR in Acromegalic Patients Completed NCT00616551 Phase 3 C2L-OCT-01 PR, 30 mg;Octreotide acetate prolonged release, 30 mg
48 Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly Completed NCT00600886 Phase 3 Pasireotide;Octreotide
49 Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly Completed NCT00499993 Phase 3 lanreotide (Autogel formulation), duration of treatment 46-48 weeks
50 Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel Completed NCT00447499 Phase 3 Somatuline Autogel (lanreotide acetate)

Search NIH Clinical Center for Hyperpituitarism

Cochrane evidence based reviews: hyperpituitarism

Genetic Tests for Hyperpituitarism

Anatomical Context for Hyperpituitarism

MalaCards organs/tissues related to Hyperpituitarism:

Pituitary, Bone, Brain, Testes, Skeletal Muscle, Liver, Heart

Publications for Hyperpituitarism

Articles related to Hyperpituitarism:

# Title Authors Year
Congenital hyperpituitarism of hypothalamic origin: a new diencephalic syndrome with endocrine manifestations. ( 14444640 )
Psychological findings in a case of von Recklinghausen's disease and hyperpituitarism. ( 13367234 )
Further evidence that hyperthyroidism (Graves' disease) is not hyperpituitarism: effects of triiodothyronine and sodium iodide. ( 14367487 )
Graves' disease: hyperthyroidism or hyperpituitarism. ( 13022743 )
Creatine-creatinine metabolism in adult and juvenile hyperpituitarism. ( 18877070 )
Hyperpituitarism and Hypopituitarism. ( 19312151 )
Thyrotoxicosis with Unilateral Exophthalmos, Hyperpituitarism, and Infantile Hemiplegia. ( 19990197 )
Case of Hyperpituitarism. ( 19984234 )

Variations for Hyperpituitarism

Expression for Hyperpituitarism

Search GEO for disease gene expression data for Hyperpituitarism.

Pathways for Hyperpituitarism

Pathways related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
12.07 GH1 GHR PRL
6 11.75 GH1 IGF1 INS
7 11.63 IGF1 IGFBP3 INS
8 11.56 IGF1 IGFBP3 INS
Show member pathways
10 11.14 GH1 GHR IGF1
11 11.1 IGF1 INS
Show member pathways
13 10.8 IGF1 IGFBP3
Show member pathways
10.41 GH1 GHR PRL

GO Terms for Hyperpituitarism

Cellular components related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.76 GH1 GHR GHRH IGF1 IGFBP3 INS
2 insulin-like growth factor ternary complex GO:0042567 9.37 IGF1 IGFBP3
3 insulin-like growth factor binding protein complex GO:0016942 9.32 IGF1 IGFBP3
4 extracellular region GO:0005576 9.32 GH1 GHR GHRH IGF1 IGFBP3 INS
5 growth hormone receptor complex GO:0070195 9.26 GH1 GHR
6 endosome lumen GO:0031904 9.13 GH1 INS PRL

Biological processes related to Hyperpituitarism according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.77 GHRH INS POMC SST TRH
2 cellular protein metabolic process GO:0044267 9.76 IGF1 IGFBP3 INS PRL
3 positive regulation of MAPK cascade GO:0043410 9.71 IGF1 IGFBP3 INS
4 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.67 GH1 IGF1 INS
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 GH1 GHR IGF1
6 activation of protein kinase B activity GO:0032148 9.62 IGF1 INS
7 hormone-mediated signaling pathway GO:0009755 9.61 GHR TRH
8 positive regulation of multicellular organism growth GO:0040018 9.61 GH1 GHR GHRH
9 positive regulation of glucose import GO:0046326 9.6 IGF1 INS
10 positive regulation of mitotic nuclear division GO:0045840 9.59 IGF1 INS
11 glucose transport GO:0015758 9.58 GH1 INS
12 response to food GO:0032094 9.58 GHR GHRH
13 regulation of multicellular organism growth GO:0040014 9.58 GHR IGF1 PRL
14 positive regulation of glycolytic process GO:0045821 9.57 IGF1 INS
15 positive regulation of glycogen biosynthetic process GO:0045725 9.56 IGF1 INS
16 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.56 GH1 GHR IGF1 INS
17 insulin-like growth factor receptor signaling pathway GO:0048009 9.55 GHR IGF1
18 growth hormone receptor signaling pathway GO:0060396 9.52 GH1 GHR
19 negative regulation of feeding behavior GO:2000252 9.51 INS TRH
20 positive regulation of JAK-STAT cascade GO:0046427 9.5 GH1 GHR PRL
21 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.33 GH1 GHR PRL
22 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.26 GH1 GHRH IGF1 IGFBP3
23 regulation of receptor activity GO:0010469 9.23 GH1 GHRH IGF1 INS POMC PRL
24 G-protein coupled receptor signaling pathway GO:0007186 10.01 GHRH INS POMC SST TRH

Molecular functions related to Hyperpituitarism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin receptor binding GO:0005158 9.26 IGF1 INS
2 hormone activity GO:0005179 9.17 GH1 IGF1 INS POMC PRL SST
3 insulin-like growth factor receptor binding GO:0005159 9.16 IGF1 INS
4 prolactin receptor binding GO:0005148 8.96 GH1 PRL

Sources for Hyperpituitarism

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
51 Novoseek
54 OMIM via Orphanet
58 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....